The next tier of EGFR resistance mutations in lung cancer
Author:
Funder
Deutsche Krebshilfe
Bundesministerium für Bildung und Forschung
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Link
https://www.nature.com/articles/s41388-020-01510-w.pdf
Reference66 articles.
1. Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, et al. Landscape of acquired resistance to osimertinib in. Cancer Discov. 2018;8:1529–39.
2. Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res. 2015;21:3913–23.
3. Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Yang JC. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol. 2017;12:567–72.
4. Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A et al. Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers. JCO Precis Oncol. 2018;2. https://doi.org/10.1200/PO.18.00126.
5. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725–37.
Cited by 87 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Kopsileuconines A−D: Bisindole alkaloids with cytotoxic activity from Kopsia hainanensis;Phytochemistry;2024-12
2. CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1;Cell Death Discovery;2024-08-29
3. Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC;Oncology and Therapy;2024-07-30
4. The structure and function of multifunctional protein ErbB3 binding protein 1 (Ebp1) and its role in diseases;Cell Biology International;2024-06-17
5. Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform;Cell Reports;2024-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3